• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

Nanoparticle delivery of aurora kinase inhibitor may improve tumor treatment [PreClinical]

byChristine YoonandJessica Lau
February 24, 2016
in Gastroenterology, Oncology, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Nanoparticle delivery of the aurora kinase inhibitor AZD2811 led to sustained drug retention in a rat model of colon adenocarcinoma.

2. As compared to treatment with the free, soluble form of AZD2811, nanoparticle administration significantly decreased tumor size and delayed the onset of tumor regrowth.

Evidence Rating Level: 2 (Good)           

Study Rundown: Aurora kinase inhibitors (AKIs) are a class of pharmacological agents designed to target tumor cell proliferation. While effective in inducing tumor cell death, AKIs have not been successful in the clinic due to major off-target toxicity effects. In this study, the authors developed a nanoparticle formulation of the AKI AZD2811 using polymer materials in order to improve treatment efficacy while limiting cytotoxicity.

Initial studies identified optimized nanoparticle formulations that would increase drug load and decrease drug release rate. Two drug-nanoparticle compound formulations made with different solvents, Accurin B and Accurin E, were tested in a rat model of colon adenocarcinoma. As compared to treatment with the prodrug AZD1152 (AZD2811 in its free, water-soluble form), nanoparticle delivery of AZD2811 resulted in improved drug retention, extending the detection of AZD2811 in tumors from 24 hours to six days after final treatment administration. Nanoparticle treatment also prolonged the antimitotic effect of the AKI. Additionally, Accurin B and Accurin E prevented tumor growth almost twice as well AZD1152. Immunohistology of bone marrow samples showed that nanoparticle treatment reduced the severity of short-term off-target toxicity caused by AZD1152. Blood tests confirmed that Accurin E caused little impact on white blood cell counts and myeloid cell numbers. Finally, the researchers additionally tested Accurin E in two mouse models of diffuse large B cell lymphoma (DLBCL) and demonstrated that nanoparticle treatment successfully delayed tumor regrowth.

Overall, these preliminary studies demonstrated the feasibility of using nanoparticle delivery of AKIs to treat tumor growth while minimizing off-target toxicity. Because the materials used in these nanoparticles are FDA-approved, progression of this treatment to human clinical trials is promising. However, more preclinical testing to establish improved survival rates, for example, is necessary.

RELATED REPORTS

#VisualAbstract: Invitation to Fecal Immunochemical Test is Noninferior to Colonoscopy Screening in Colorectal Cancer Mortality

Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer

#VisualAbstract: Intravenous Lidocaine Does Not Improve Gut Function Recovery in Minimally Invasive Colonic Surgery

Click to read the study in Science Translational Medicine

Click to read an accompanying editorial in Science Translational Medicine

Relevant Reading: MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

In-Depth [animal study]: In nude athymic rats grafted with human colon adenocarcinoma tumors, 25mg/kg of AZD1152, Accurin B, or Accurin E was administered intravenously. AZD2811 was present in resected tumors collected 6 days after final nanoparticle administration, while drug was not detected in samples from animals treated with the prodrug even 24 hours after treatment.

By measuring levels of phosphorylated histone H3 (pHH3), a marker of cell division, the authors found that AZD1152 treatment led to decreased cell proliferation after the first 6 hours post-treatment. However, pHH3 levels returned to levels comparable to that of the placebo-treated group (treated with empty nanoparticles) within 24 hours. In contrast, Accurin B and Accurin E sustained lowered pHH3 levels for up to 48 and 96 hours, respectively.

Tumor volume measurements 17 days after initial treatment determined that Accurin B and Accurin E treatment lead to decreased growth by 92% and 101%, respectively, as compared to AZD1152 treatment, which resulted in only a 58% volume reduction (n=10). Using immunohistochemistry, the cellularity of bone marrow samples was scored from 0 (no change) to 4 (severe).  AZD1152 caused mild-to-moderate change (2-3) 5 days after treatment. In contrast, nanoparticle administration showed no-to-minimal change (0-1) with nanoparticle administration. Accurin E also decreased white blood cell numbers to a range comparable to those of placebo nanoparticles (n=2 to 5).

Finally, several additional xenograft mouse models were used to validate the findings. A colon adenocarcinoma cell line and two DLBCL cell lines were subcutaneously injected into mice to establish tumors. In all three models, Accurin E was able to significantly delay the regrowth of tumors as compared to placebo treatment and AZD1152 administration (n=10 to 12).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: colon cancer
Previous Post

Oral corticosteroids and NSAIDs similarly effective in the treatment of acute gout

Next Post

Transcatheter aortic valve replacement in women linked to increased complications, decreased mortality

RelatedReports

#VisualAbstract: Invitation to Fecal Immunochemical Test is Noninferior to Colonoscopy Screening in Colorectal Cancer Mortality
StudyGraphics

#VisualAbstract: Invitation to Fecal Immunochemical Test is Noninferior to Colonoscopy Screening in Colorectal Cancer Mortality

April 7, 2025
Development of a risk index for colorectal cancer screening
Chronic Disease

Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer

April 3, 2025
#VisualAbstract: Intravenous Lidocaine Does Not Improve Gut Function Recovery in Minimally Invasive Colonic Surgery
StudyGraphics

#VisualAbstract: Intravenous Lidocaine Does Not Improve Gut Function Recovery in Minimally Invasive Colonic Surgery

December 9, 2024
Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs
Gastroenterology

Fluorouracil, leucovorin and irinotecan plus panitumumab for the treatment of metastatic colorectal cancer

November 27, 2024
Next Post
Transcatheter aortic valve replacement provides only minor benefit to quality of life

Transcatheter aortic valve replacement in women linked to increased complications, decreased mortality

Nanoparticle delivery of aurora kinase inhibitor may improve tumor treatment [PreClinical]

Zika viral genome detected in the amniotic fluid of two fetuses with microcephaly

Drug reformulation may improve treatment of Niemann-Pick type C disease [PreClinical]

Drug reformulation may improve treatment of Niemann-Pick type C disease [PreClinical]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Twice-yearly lenacapavir prevents HIV more effectively than daily F/TDF
  • #VisualAbstract: Efruxifermin Did Not Reduce Liver Fibrosis in Compensated Liver Cirrhosis Caused by MASH
  • Diabetic polyneuropathy observed to have dynamic changes overtime
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.